Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Intellia Therapeutics, Inc. (NTLA) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases"
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress - Completed identification of all patients for the Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema - Plans to initiate a global pivotal Phase 3 study of NTLA-2002 as early as Q3 2024, subject to regulatory feedback - On track to submit IND application in September for a global pivotal study of NTLA-2001 for the treatment of transthyretin amyloidosis with cardiomyopathy; study initiation anticipated by year-end 2023, subject to regulatory feedback - Plans to present additional clinical data in 2023 from the ongoing NTLA-2001 first-in-human study by year-end - Expects to submit a Clinical Trial Application by year-end for NTLA-3001, Intellia’s first in vivo inser..."
07/31/2023 144 Form 144 - Report of proposed sale of securities:
07/06/2023 144 Form 144 - Report of proposed sale of securities:
06/16/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "CERTIFICATE OF AMENDMENT OF SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INTELLIA THERAPEUTICS, INC. Intellia Therapeutics, Inc. , a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware , DOES HEREBY CERTIFY: 1. That the name of this corporation is Intellia Therapeutics, Inc. and that this corporation was originally incorporated pursuant to the General Corporation Law on May 7, 2014 under the name AZRN, Inc. 2. That the Board of Directors of the Corporation duly adopted resolutions proposing to amend the Second Amended and Restated Certificate of Incorporation of the Corporation, declaring said amendment to be advisable and in the best interests of the Corporation and its stockholders, and authorizing the appropriate ..."
06/12/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Intellia Therapeutics Announces New Positive Clinical Data from Phase 1study of"
06/05/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. from Its Board of Directors CAMBRIDGE, Mass., June 5, 2023 — Intellia Therapeutics, Inc. , a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that Jean-François Formela, M.D. is retiring from its board of directors, effective June 15, 2023. “Working with the team at Intellia and seeing the company's transformation from an idea to a leader in genome editing has been one of the most exciting journeys in my career,” said Jean-François Formela, M.D. “I am confident this is just the beginning for John and his team. I can't wait to see Intellia's next chapter and how they will transform the future..."
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
Docs: "Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress - Dosed first patient in the global Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema - Expects to complete enrollment in the Phase 2 study of NTLA-2002 in 2H 2023 - Plans to submit IND application in mid-2023 for a global pivotal study of NTLA-2001 for the treatment of transthyretin amyloidosis with cardiomyopathy; study initiation anticipated by year-end 2023, subject to regulatory feedback - On track to present additional clinical data in 2023 from both ongoing NTLA-2001 and NTLA-2002 first-in-human studies - Progressing next wave of clinical candidates, including NTLA-3001 and NTLA-2003, and advancing novel gene editing capabilities - Ended the first quarter o..."
05/01/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/18/2023 ARS Form ARS - Annual Report to Security Holders:
04/18/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
04/17/2023 8-K Quarterly results
03/24/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
03/02/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Intellia Therapeutics Announces FDA Clearance of Investigational New Drug"
02/23/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/23/2023 10-K Annual Report for the period ended December 31, 2022
02/23/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress - Initiated the global Phase 2 study of NTLA-2002, a CRISPR-based, potential single-dose treatment for hereditary angioedema - Submitted IND application for NTLA-2002 to enable patient enrollment in the U.S. for the Phase 2 study - Plans to submit IND application in mid-2023 for global pivotal study of NTLA-2001 for the treatment of transthyretin amyloidosis with cardiomyopathy; global pivotal study initiation anticipated by year-end 2023 - On track to present additional clinical data in 2023 from both ongoing NTLA-2001 and NTLA-2002 first-in-human studies - Progressing IND-enabling activities for two alpha-1 antitrypsin deficiency candidates, NTLA-2003 and NTLA-3001; ..."
02/10/2023 SC 13G/A ARK Investment Management LLC reports a 11.2% stake in Intellia Therapeutics, Inc.
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 9.3% stake in Intellia Therapeutics Inc.
02/09/2023 SC 13G/A FMR LLC reports a 2.9% stake in INTELLIA THERAPEUTICS INC
01/25/2023 SC 13G BlackRock Inc. reports a 8.7% stake in Intellia Therapeutics, Inc.
01/05/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ...
Docs: "Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones - Strategic priorities focus on late-stage development of its CRISPR-based medicines while continuing to expand and validate its industry-leading genome editing platform - Submit IND application in mid-2023 as part of a global pivotal study of NTLA-2001 for the treatment of transthyretin amyloidosis with cardiomyopathy; study initiation anticipated by year-end 2023 - Submit IND application for NTLA-2002 for the treatment of hereditary angioedema and initiate global Phase 2 study in 1H 2023 - Present additional clinical data in 2023 from both ongoing NTLA-2001 and NTLA-2002 first-in-human studies - Progress first CRISPR-based gene insertion investigational therapy in humans; submit IND or equivalent fi..."
12/01/2022 8-K Quarterly results
12/01/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
11/14/2022 8-K Quarterly results
11/07/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin Amyloidosis at the American Heart Association Scientific Sessions 2022 - Data presented in late-breaking oral presentation demonstrated deep and consistent TTR reduction following a single dose of NTLA-2001 in patients with ATTR amyloidosis with cardiomyopathy - Greater than 90% mean serum TTR reductions after a single dose of NTLA-2001 were sustained at both doses tested, with follow-up now reaching four to six months - NTLA-2001 was generally well-tolerated CAMBRIDGE, Mass., Nov. 5, 2022 – Intellia Therapeutics, Inc. , a leading clinical-stage genome editing company focused on developing potentially curative therapeu..."
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/03/2022 8-K Quarterly results
09/16/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin Amyloidosis",
"Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema"
08/04/2022 10-Q Quarterly Report for the period ended June 30, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy